TSE:NRI

Nuvo Pharmaceuticals Inc. (NRI.TO) Competitors

C$36.60
+0.66 (+1.84 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
C$36.60
Now: C$36.60
C$36.60
50-Day Range
C$0.91
MA: C$24.39
C$39.58
52-Week Range
C$0.43
Now: C$36.60
C$1.20
VolumeN/A
Average Volume19,371 shs
Market CapitalizationC$416.80 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) Vs. TRIL, CXR, APS, BU, TH, and BLU

Should you be buying NRI stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Nuvo Pharmaceuticals Inc. (NRI.TO), including Trillium Therapeutics (TRIL), Concordia International (CXR), Aptose Biosciences (APS), Burcon NutraScience (BU), Theratechnologies (TH), and BELLUS Health (BLU).

Trillium Therapeutics (TSE:TRIL) and Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Trillium Therapeutics and Nuvo Pharmaceuticals Inc. (NRI.TO), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trillium Therapeutics0000N/A
Nuvo Pharmaceuticals Inc. (NRI.TO)00103.00

Trillium Therapeutics presently has a consensus price target of C$25.00, indicating a potential upside of 101.78%. Given Trillium Therapeutics' higher possible upside, equities analysts plainly believe Trillium Therapeutics is more favorable than Nuvo Pharmaceuticals Inc. (NRI.TO).

Profitability

This table compares Trillium Therapeutics and Nuvo Pharmaceuticals Inc. (NRI.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trillium TherapeuticsN/AN/AN/A
Nuvo Pharmaceuticals Inc. (NRI.TO)N/AN/AN/A

Earnings and Valuation

This table compares Trillium Therapeutics and Nuvo Pharmaceuticals Inc. (NRI.TO)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trillium TherapeuticsC$148,000.008,625.53C$-90,772,073.00C($0.88)-14.06
Nuvo Pharmaceuticals Inc. (NRI.TO)C$76.09 million5.48C$-6,980,844.00C($0.61)-59.71

Nuvo Pharmaceuticals Inc. (NRI.TO) has higher revenue and earnings than Trillium Therapeutics. Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than Trillium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Nuvo Pharmaceuticals Inc. (NRI.TO) beats Trillium Therapeutics on 4 of the 7 factors compared between the two stocks.

Concordia International (TSE:CXR) and Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Concordia International and Nuvo Pharmaceuticals Inc. (NRI.TO), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Concordia International0000N/A
Nuvo Pharmaceuticals Inc. (NRI.TO)00103.00

Profitability

This table compares Concordia International and Nuvo Pharmaceuticals Inc. (NRI.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Concordia InternationalN/AN/AN/A
Nuvo Pharmaceuticals Inc. (NRI.TO)N/AN/AN/A

Earnings and Valuation

This table compares Concordia International and Nuvo Pharmaceuticals Inc. (NRI.TO)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Concordia InternationalC$569.62 million0.00C$17.20 billionC$351.68N/A
Nuvo Pharmaceuticals Inc. (NRI.TO)C$76.09 million5.48C$-6,980,844.00C($0.61)-59.71

Concordia International has higher revenue and earnings than Nuvo Pharmaceuticals Inc. (NRI.TO). Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than Concordia International, indicating that it is currently the more affordable of the two stocks.

Summary

Concordia International beats Nuvo Pharmaceuticals Inc. (NRI.TO) on 4 of the 5 factors compared between the two stocks.

Aptose Biosciences (TSE:APS) and Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Aptose Biosciences and Nuvo Pharmaceuticals Inc. (NRI.TO), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aptose Biosciences00203.00
Nuvo Pharmaceuticals Inc. (NRI.TO)00103.00

Aptose Biosciences presently has a consensus price target of C$12.00, indicating a potential upside of 88.68%. Given Aptose Biosciences' higher possible upside, equities analysts plainly believe Aptose Biosciences is more favorable than Nuvo Pharmaceuticals Inc. (NRI.TO).

Earnings and Valuation

This table compares Aptose Biosciences and Nuvo Pharmaceuticals Inc. (NRI.TO)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/AN/AC($0.85)-7.52
Nuvo Pharmaceuticals Inc. (NRI.TO)C$76.09 million5.48C$-6,980,844.00C($0.61)-59.71

Aptose Biosciences has higher earnings, but lower revenue than Nuvo Pharmaceuticals Inc. (NRI.TO). Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aptose Biosciences and Nuvo Pharmaceuticals Inc. (NRI.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aptose BiosciencesN/AN/AN/A
Nuvo Pharmaceuticals Inc. (NRI.TO)N/AN/AN/A

Summary

Aptose Biosciences beats Nuvo Pharmaceuticals Inc. (NRI.TO) on 3 of the 5 factors compared between the two stocks.

Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.

Analyst Ratings

This is a summary of current recommendations and price targets for Nuvo Pharmaceuticals Inc. (NRI.TO) and Burcon NutraScience, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvo Pharmaceuticals Inc. (NRI.TO)00103.00
Burcon NutraScience00103.00

Burcon NutraScience has a consensus target price of C$5.00, indicating a potential downside of 2.72%. Given Burcon NutraScience's higher possible upside, analysts plainly believe Burcon NutraScience is more favorable than Nuvo Pharmaceuticals Inc. (NRI.TO).

Valuation & Earnings

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and Burcon NutraScience's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo Pharmaceuticals Inc. (NRI.TO)C$76.09 million5.48C$-6,980,844.00C($0.61)-59.71
Burcon NutraScienceC$12,045.0045,703.54C$107,101.00C$0.005,140.00

Burcon NutraScience has lower revenue, but higher earnings than Nuvo Pharmaceuticals Inc. (NRI.TO). Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and Burcon NutraScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvo Pharmaceuticals Inc. (NRI.TO)N/AN/AN/A
Burcon NutraScienceN/AN/AN/A

Summary

Burcon NutraScience beats Nuvo Pharmaceuticals Inc. (NRI.TO) on 5 of the 6 factors compared between the two stocks.

Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.

Analyst Ratings

This is a summary of current recommendations and price targets for Nuvo Pharmaceuticals Inc. (NRI.TO) and Theratechnologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvo Pharmaceuticals Inc. (NRI.TO)00103.00
Theratechnologies02002.00

Theratechnologies has a consensus target price of C$3.75, indicating a potential downside of 24.55%. Given Theratechnologies' higher possible upside, analysts plainly believe Theratechnologies is more favorable than Nuvo Pharmaceuticals Inc. (NRI.TO).

Valuation & Earnings

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and Theratechnologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo Pharmaceuticals Inc. (NRI.TO)C$76.09 million5.48C$-6,980,844.00C($0.61)-59.71
TheratechnologiesC$66.05 million7.06C$-34,627,329.00C($0.37)-13.47

Nuvo Pharmaceuticals Inc. (NRI.TO) has higher revenue and earnings than Theratechnologies. Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and Theratechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvo Pharmaceuticals Inc. (NRI.TO)N/AN/AN/A
TheratechnologiesN/AN/AN/A

Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Nuvo Pharmaceuticals Inc. (NRI.TO) and BELLUS Health, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvo Pharmaceuticals Inc. (NRI.TO)00103.00
BELLUS Health01202.67

Earnings and Valuation

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and BELLUS Health's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo Pharmaceuticals Inc. (NRI.TO)C$76.09 million5.48C$-6,980,844.00C($0.61)-59.71
BELLUS HealthC$15,000.0029,768.06C$-42,145,306.00C($0.54)-10.59

Nuvo Pharmaceuticals Inc. (NRI.TO) has higher revenue and earnings than BELLUS Health. Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than BELLUS Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and BELLUS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvo Pharmaceuticals Inc. (NRI.TO)N/AN/AN/A
BELLUS HealthN/AN/AN/A

Summary

BELLUS Health beats Nuvo Pharmaceuticals Inc. (NRI.TO) on 4 of the 7 factors compared between the two stocks.


Nuvo Pharmaceuticals Inc. (NRI.TO) Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
TRIL
Trillium Therapeutics
0.9$12.39+5.4%C$1.28 billionC$148,000.00-14.06
Concordia International logo
CXR
Concordia International
0.7N/AN/AC$1.22 billionC$569.62 million0.07High Trading Volume
APS
Aptose Biosciences
1.3$6.36+3.9%C$565.31 millionN/A-7.52
BU
Burcon NutraScience
1.2$5.14+5.4%C$550.50 millionC$12,045.005,140.00Gap Down
Theratechnologies logo
TH
Theratechnologies
0.7$4.97+4.0%C$466.39 millionC$66.05 million-13.47
BLU
BELLUS Health
0.5$5.70+4.4%C$446.52 millionC$15,000.00-10.59
ProMetic Life Sciences logo
PLI
ProMetic Life Sciences
0.5N/AN/AC$315.66 millionC$39.91 million-0.22
NEPT
Neptune Wellness Solutions
1.2$1.64+7.9%C$271.41 millionC$52.78 million-1.21
MDNA
Medicenna Therapeutics
0.5$5.00+1.6%C$264.51 millionN/A-16.18
EMC
Emblem
0.5$1.88+1.6%$248.31 million$5.71 million-9.89
IMV logo
IMV
IMV
1.2$3.55+2.0%C$240.37 millionC$3,000.00-6.14
ONC
Oncolytics Biotech
1.2$4.13+20.8%C$217.94 millionN/A-7.38High Trading Volume
News Coverage
Gap Down
RVX
Resverlogix
0.7$0.91+5.5%C$212.93 millionN/A82.73Upcoming Earnings
News Coverage
Gap Down
ATE
Antibe Therapeutics
1.3$4.65+4.9%C$211.61 millionC$9.33 million-5.91
FRX
Fennec Pharmaceuticals
0.5$7.51+4.1%C$195.28 millionC$170,000.00-7.84
IPA
ImmunoPrecise Antibodies
0.4$15.29+0.8%C$123.03 millionC$17.18 million-71.45
HBP
Helix BioPharma
0.5$0.83+10.8%C$117.14 millionN/A-15.09
ACST
Acasti Pharma Inc. (ACST.V)
0.8$0.64+6.3%C$88.79 millionC$81,000.0018.82News Coverage
NVH
Novoheart
0.5$0.53+1.9%C$79.23 millionC$423,500.00-13.95
MBX
Microbix Biosystems
0.9$0.62+11.3%C$67.86 millionC$11.64 million-12.16High Trading Volume
PDP
Pediapharm
0.5$0.30+1.7%C$66.36 millionC$11.16 million-4.11
PMN
ProMIS Neurosciences
0.5$0.22+4.7%C$65.78 millionC$1,787.00-10.75
SBM
Sirona Biochem
0.5$0.35+8.6%C$58.80 millionC$123,870.00-26.92Gap Up
COV
Covalon Technologies
0.6$1.41+0.7%C$37.44 millionC$23.84 million-5.92
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.27+9.4%C$34.02 millionC$13.02 million-0.38
IGX
IntelGenx Technologies
0.9$0.66+13.6%C$30.87 millionC$1.54 million-10.15High Trading Volume
News Coverage
QPT
Quest PharmaTech
0.8$0.11+0.0%C$21.76 millionC$38,871.000.17High Trading Volume
Gap Down
CZO
Ceapro
0.6$0.79+8.9%C$21.65 millionC$16.14 million23.94
CTX
Crescita Therapeutics
0.6$0.85+1.2%C$17.55 millionC$15.64 million425.00
KNE
Kane Biotech
0.4$0.16+6.3%C$14.12 millionC$1.34 million-4.57
GSD
Devonian Health Group
0.5$0.27+3.7%C$13.96 millionC$1.59 million-5.63Gap Up
PAS
Pascal Biosciences
0.6$0.09+5.6%C$12.70 millionN/A-4.09
NSP
Naturally Splendid Enterprises
0.6$0.06+0.0%C$11.06 millionC$2.03 million-1.40Gap Down
MPH
Medicure
0.7$1.60+0.0%C$10.80 millionC$12.71 million-1.03Gap Up
BTI
Bioasis Technologies
0.7$0.44+11.4%C$10.16 millionC$4.12 million40.00
HEM
Hemostemix
0.6$0.48+2.1%C$9.07 millionN/A-2.86
ICO
iCo Therapeutics
0.5$0.11+0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.36+1.4%C$6.94 millionC$5.60 million6.67
IOT
Innovotech
0.8$0.15+3.3%C$6.52 millionC$1.04 million75.00
BCT
BriaCell Therapeutics
0.5$4.90+30.6%C$4.48 millionN/A-1.58High Trading Volume
Gap Down
RVV
Revive Therapeutics
0.5$0.08+12.5%C$3.62 millionN/A-3.64High Trading Volume
News Coverage
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04+71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03+16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01+0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
COM
138267 (COM.TO)
0.5$2.95+2.7%C$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.7N/AN/AC$0.00C$267.59 million47.20
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.